摘要
目的:探讨骨髓增生异常综合征(MDS)髓系细胞免疫表型的变化及其临床意义。方法:应用一组单克隆抗体,采用免疫酶标法对51例MDS、21例再生障碍性贫血(AA)、21例阵发性睡眠性血红蛋白尿症(PNH)、10例急性髓系白血病(AML)患者及15名正常人骨髓细胞膜表面抗原CD13、CD14、CD33和CD15进行检测,同时还检测MDS患者的骨髓细胞形态、染色体核型及姊妹染色单体分染(SCD),并按分型进行促分化、促造血和小剂量化疗。结果:MDS骨髓单个核细胞较正常人表达CD14(37.92%对16.67%)、CD13、CD33(29.63%,31.83%对16.41%,15.12%)明显增加,而CD15(26.14%对40.83%)明显减少;MDS骨髓单个核细胞CD14、CD13、CD33抗原表达还明显高于AA(11.62%,14.19%,12.01%)和PNH(14.46%,14.19%,12.01%),CD13、CD33低于AML(61.24%,52.31%);低危组MDS(RA/RAS)较高危组MDS(RAEB-t)的CD14(27.03%对54.27%)、CD13(24.56%对36.41%)、CD33?
Objective:To explore the immunophenotype of myeloid cells in myelodysplastic syndromes and its clinical implications.Methods:A panel of monoclonal antibodies was used to detect CD 13 ,CD 33 ,CD 15 and CD 14 on the membrane surfaces of myeloid cells in the bone marrow from 51 patients with myelodysplastic syndromes (MDS),21 with aplastic anemia (AA),21 with paroxysmal nocturnal hemoglobinuria (PNH),and 15 normal subjects,by immunoenzymatic assay.The morphology and chromosome karyotype of bone marrow cells of MDS patients were also examined.Results:CD 14 + cells, CD 13 + cells and CD 33 + cells in the bone marrow were more in MDS patients than in normal controls,AA patients and PNH patients.CD 15 + cells in the bone marrow were less in MDS patients than in normal controls.The percentages of CD 14 ,CD 13 and CD 33 positive cells in the bone marrow of MDS patients were related to the percentage of myeloblast, the chromosomal aberrations and the response to treatment.Conclusion:There was an immunophenotypic misexpression of myeloid cells in MDS patients.Immunophenotype analysis of myeloid cells might be useful for the diagnosis and directing treatment in MDS patients.
出处
《中华血液学杂志》
CAS
CSCD
北大核心
1997年第2期80-83,共4页
Chinese Journal of Hematology
基金
卫生部回国人员科研启动基金